BR112022023937A2 - Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina - Google Patents
Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropinaInfo
- Publication number
- BR112022023937A2 BR112022023937A2 BR112022023937A BR112022023937A BR112022023937A2 BR 112022023937 A2 BR112022023937 A2 BR 112022023937A2 BR 112022023937 A BR112022023937 A BR 112022023937A BR 112022023937 A BR112022023937 A BR 112022023937A BR 112022023937 A2 BR112022023937 A2 BR 112022023937A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage forms
- oral dosage
- solid oral
- gonadotropin
- releasing hormone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
FORMAS DE DOSAGEM ORAL SÓLIDAS DE COMBINAÇÃO DE ANTAGONISTAS DO HORMÔNIO LIBERADOR DE GONADOTROPINA. A presente divulgação inclui formas de dosagem oral sólida de combinação com 40 mg de N-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metoxi3-piridazinil)-2,4-dioxo-1,2,3,4-tetra-hidrotieno[2,3-d]pirimidin-6-il)fenil)-N'- metoxiureia, ou uma quantidade correspondente de um sal farmaceuticamente aceitável do mesmo, e reposição hormonal medicamentos. Também são fornecidos processos para fazer e usar as formas de dosagem oral sólidas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032469P | 2020-05-29 | 2020-05-29 | |
PCT/EP2021/064280 WO2021239917A1 (en) | 2020-05-29 | 2021-05-27 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022023937A2 true BR112022023937A2 (pt) | 2022-12-27 |
Family
ID=76305879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022023937A BR112022023937A2 (pt) | 2020-05-29 | 2021-05-27 | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230165800A1 (pt) |
EP (1) | EP4157227A1 (pt) |
JP (1) | JP2023528014A (pt) |
KR (1) | KR20230028732A (pt) |
CN (1) | CN115666531A (pt) |
AR (1) | AR122175A1 (pt) |
AU (1) | AU2021278303A1 (pt) |
BR (1) | BR112022023937A2 (pt) |
CA (1) | CA3185151A1 (pt) |
CL (1) | CL2022003338A1 (pt) |
CO (1) | CO2022019160A2 (pt) |
EC (1) | ECSP22098275A (pt) |
IL (1) | IL298587A (pt) |
MX (1) | MX2022015003A (pt) |
PE (1) | PE20230859A1 (pt) |
UY (1) | UY39229A (pt) |
WO (1) | WO2021239917A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ752916A (en) | 2016-09-30 | 2022-09-30 | Takeda Pharmaceuticals Co | Methods of treating uterine fibroids and endometriosis |
CN115227648B (zh) * | 2022-08-03 | 2023-09-29 | 南昌大学 | 一种瑞卢戈利固体自微乳及其制备方法和应用 |
CN115068421B (zh) * | 2022-08-03 | 2023-08-04 | 南昌大学 | 一种瑞卢戈利纳米混悬液及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101074462B1 (ko) | 2003-01-29 | 2011-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 화합물 및 그 용도 |
EP4119564A1 (en) | 2012-09-28 | 2023-01-18 | Takeda Pharmaceutical Company Limited | Production method of thienopyrimidine derivative |
DK3263110T3 (da) | 2015-02-26 | 2023-07-31 | Takeda Pharmaceuticals Co | Tablet, som omfatter et methoxyurinstofderivat og mannitolpartikler |
JP7062673B2 (ja) | 2016-09-30 | 2022-05-06 | ミオバント サイエンシズ ゲーエムベーハー | 前立腺がんの治療 |
NZ752916A (en) | 2016-09-30 | 2022-09-30 | Takeda Pharmaceuticals Co | Methods of treating uterine fibroids and endometriosis |
-
2021
- 2021-05-27 MX MX2022015003A patent/MX2022015003A/es unknown
- 2021-05-27 UY UY0001039229A patent/UY39229A/es unknown
- 2021-05-27 WO PCT/EP2021/064280 patent/WO2021239917A1/en unknown
- 2021-05-27 AU AU2021278303A patent/AU2021278303A1/en active Pending
- 2021-05-27 CN CN202180037887.XA patent/CN115666531A/zh active Pending
- 2021-05-27 BR BR112022023937A patent/BR112022023937A2/pt unknown
- 2021-05-27 EP EP21730501.0A patent/EP4157227A1/en active Pending
- 2021-05-27 PE PE2022002787A patent/PE20230859A1/es unknown
- 2021-05-27 IL IL298587A patent/IL298587A/en unknown
- 2021-05-27 AR ARP210101422A patent/AR122175A1/es unknown
- 2021-05-27 CA CA3185151A patent/CA3185151A1/en active Pending
- 2021-05-27 KR KR1020227046030A patent/KR20230028732A/ko active Search and Examination
- 2021-05-27 JP JP2022572798A patent/JP2023528014A/ja active Pending
-
2022
- 2022-11-25 CL CL2022003338A patent/CL2022003338A1/es unknown
- 2022-11-28 US US18/070,341 patent/US20230165800A1/en active Pending
- 2022-12-28 CO CONC2022/0019160A patent/CO2022019160A2/es unknown
- 2022-12-29 EC ECSENADI202298275A patent/ECSP22098275A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021278303A1 (en) | 2023-02-09 |
US20230165800A1 (en) | 2023-06-01 |
CL2022003338A1 (es) | 2023-06-30 |
EP4157227A1 (en) | 2023-04-05 |
CA3185151A1 (en) | 2021-12-02 |
PE20230859A1 (es) | 2023-05-30 |
ECSP22098275A (es) | 2023-01-31 |
IL298587A (en) | 2023-01-01 |
MX2022015003A (es) | 2023-03-03 |
UY39229A (es) | 2021-12-31 |
CN115666531A (zh) | 2023-01-31 |
AR122175A1 (es) | 2022-08-24 |
KR20230028732A (ko) | 2023-03-02 |
WO2021239917A1 (en) | 2021-12-02 |
JP2023528014A (ja) | 2023-07-03 |
CO2022019160A2 (es) | 2023-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022023937A2 (pt) | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina | |
WO2018060463A3 (en) | Treatment of prostate cancer | |
AR109816A2 (es) | Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 | |
AR052843A1 (es) | Formas de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada | |
SI2529622T1 (en) | Bruton tyrosine kinase inhibitors | |
TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
V Golubeva et al. | Metabotropic glutamate receptors in central nervous system diseases | |
DOP2013000169A (es) | Compuesto para uso en el tratamiento de la artritis | |
NO20062051L (no) | Farmasoytisk virkestoffinneholdende formulering med belegg | |
BR0107564A (pt) | Composição de gliburida | |
NZ598918A (en) | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | |
EA202190650A1 (ru) | Замедленная доставка ангиопоэтин-подобных полипептидов 3 | |
CL2007001663A1 (es) | Uso de un antagonista de cgrp de formula definida (a), sus enantiomeros, sus diastereomeros, sus mezclas y sus sales para preparar un medicamento util para prevenir o tratar el dolor visceral. | |
MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
EA200701681A1 (ru) | Пероральная лекарственная форма, содержащая росиглитазон | |
PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
CN101090716A (zh) | 治疗hcv病症的方法 | |
RS54293B1 (en) | PHARMACEUTICAL COMBINATION | |
AR115913A1 (es) | Formas de dosificación oral biodisponibles, uso, métodos | |
AR060956A1 (es) | Derivados de 1-[4-[benzoil(metil)amino]-3-(fenil)butil]azetidina para el trata-miento de desordenes gastrointestinales | |
BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
MX2021009761A (es) | Compuesto de pirimidinil-3,8-diazabiciclo [3.2.1]octanilmetanona cristalina y uso de este. | |
AR038858A1 (es) | Combinacion | |
CL2023001791A1 (es) | Formas solidas de un inhibidor de eif4e | |
WO2007083096A3 (en) | N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin |